Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Edgewood Oncology Announces New Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma
Tuesday, April 29, 2025Edgewood Oncology a clinicalstage biotechnology company focused on delivering BTXA to patients with hematologic malignancies and geneticallydefined solid tumors today announced the presentation of new preclinical data presented
Ryvu Therapeutics Presents Preclinical Data on RVU305, ONCO Prime, and Next-Generation ADCs at AACR and ADC Payload Summit
Monday, April 28, 2025Ryvu Therapeuticsa clinicalstage drug discovery and development company focusing on innovative therapies targeting emerging areas in oncology is presenting preclinical data from its synthetic lethality pipeline at the AACR Annual Meeting
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
Friday, April 25, 2025Akoya Biosciences Inc The Spatial Biology Company today announced the availability of a new assay designed to advance antibodydrug conjugate ADC development in breast cancer The new assay will be featured alongside customergenerated realworld
Turbine Launches the World’s First Virtual Lab Using Cell Simulations
Friday, April 25, 2025In a landmark move the FDA recently announced plans to phase out the requirement for animal testing in drug development encouraging the use of humanrelevant in silico methods instead This shift reflects a broader transformation
Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
Thursday, April 24, 2025Epicrispr Biotechnologies a biotechnology company focused on developing curative therapies today announced a partnership with Springbok Analytics to incorporate advanced AIdriven muscle MRI imaging and analysis into its firstinhuman
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
Thursday, April 24, 2025Zhejiang Doer Biologics Co Ltd a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers today announces that DR its firstinclass FIC
CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License from Chinese NMPA
Wednesday, April 23, 2025CARBOGEN AMCIS a Switzerlandbased pharmaceutical process development and Active Pharmaceutical Ingredient API manufacturing company is pleased to announce that its Shanghai facility has successfully obtained its first Drug Manufacturing
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday, April 22, 2025Avidity Biosciences Inc a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates AOCs today announced that on April the Human Capital Management Committee of Aviditys Board of Di...
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Tuesday, April 22, 2025Jazz Pharmaceuticals plc today announced the successful completion of its acquisition of Chimerix Inc Chimerix for approximately million in cash Chimerix is now a wholly owned subsidiary of Jazz
Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast cancer
Monday, April 21, 2025Positive highlevel results from a planned interim analysis of the DESTINYBreast Phase III trial showed Enhertu trastuzumab deruxtecan in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement
